QQ客服 官方微博 反馈留言

浏览/检索结果: 共10条，第1-10条 帮助 限定条件 发表日期：2017    专题：合肥物质科学研究院    第一署名单位    第一作者单位    通讯作者单位     已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 Gemcitabine and Chk1 Inhibitor AZD7762 Synergistically Suppress the Growth of Lkb1-Deficient Lung Adenocarcinoma 期刊论文 CANCER RESEARCH, 2017, 卷号: 77, 期号: 18, 页码: 5068-5076 作者:  Liu, Yan;  Li, Yuyang;  Wang, Xiaoen;  Liu, Feiyang;  Gao, Peng 收藏  |  浏览/下载：34/0  |  提交时间：2018/08/16 Discovery of (R)-1-(3-(4-Amino-3-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (CHMFL-EGFR-202) as a Novel Irreversible EGFR Mutant Kinase Inhibitor with a Distinct Binding Mode 期刊论文 JOURNAL OF MEDICINAL CHEMISTRY, 2017, 卷号: 60, 期号: 7, 页码: 2944-2962 作者:  Wang, Aoli 收藏  |  浏览/下载：34/0  |  提交时间：2018/07/26 Discovery of (R)-1-(3-(4-Amino-3-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (CHMFL-EGFR-202) as a Novel Irreversible EGFR Mutant Kinase Inhibitor with a Distinct Binding Mode 期刊论文 JOURNAL OF MEDICINAL CHEMISTRY, 2017, 卷号: 60, 期号: 7, 页码: 2944-2962 作者:  Wang, Aoli;  Li, Xixiang;  Wu, Hong;  Zou, Fengming;  Yan, Xiao-E 收藏  |  浏览/下载：41/0  |  提交时间：2018/07/26 Discovery of (R)-1-(3-(4-Amino-3-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (CHMFL-EGFR-202) as a Novel Irreversible EGFR Mutant Kinase Inhibitor with a Distinct Binding Mode 期刊论文 JOURNAL OF MEDICINAL CHEMISTRY, 2017, 卷号: 60, 期号: 7, 页码: 2944-2962 作者:  Wang, Aoli;  Li, Xixiang;  Wu, Hong;  Zou, Fengming;  Yan, Xiao-E 收藏  |  浏览/下载：33/0  |  提交时间：2018/07/26 Discovery of (R)-1-(3-(4-Amino-3-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (CHMFL-EGFR-202) as a Novel Irreversible EGFR Mutant Kinase Inhibitor with a Distinct Binding Mode 期刊论文 JOURNAL OF MEDICINAL CHEMISTRY, 2017, 卷号: 60, 期号: 7, 页码: 2944-2962 作者:  Wang, Aoli;  Li, Xixiang;  Wu, Hong;  Zou, Fengming;  Yan, Xiao-E 收藏  |  浏览/下载：30/0  |  提交时间：2018/07/26 Discovery of (R)-1-(3-(4-Amino-3-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (CHMFL-EGFR-202) as a Novel Irreversible EGFR Mutant Kinase Inhibitor with a Distinct Binding Mode 期刊论文 JOURNAL OF MEDICINAL CHEMISTRY, 2017, 卷号: 60, 期号: 7, 页码: 2944-2962 作者:  Wang, Aoli;  Li, Xixiang;  Wu, Hong;  Zou, Fengming;  Yan, Xiao-E 收藏  |  浏览/下载：35/0  |  提交时间：2018/07/26 Discovery of (R)-1-(3-(4-Amino-3-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (CHMFL-EGFR-202) as a Novel Irreversible EGFR Mutant Kinase Inhibitor with a Distinct Binding Mode 期刊论文 JOURNAL OF MEDICINAL CHEMISTRY, 2017, 卷号: 60, 期号: 7, 页码: 2944-2962 作者:  Wang, Aoli;  Li, Xixiang;  Wu, Hong;  Zou, Fengming;  Yan, Xiao-E 收藏  |  浏览/下载：26/0  |  提交时间：2018/07/26 Discovery of (R)-1-(3-(4-Amino-3-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (CHMFL-EGFR-202) as a Novel Irreversible EGFR Mutant Kinase Inhibitor with a Distinct Binding Mode 期刊论文 JOURNAL OF MEDICINAL CHEMISTRY, 2017, 卷号: 60, 期号: 7, 页码: 2944-2962 作者:  Wang, Aoli;  Li, Xixiang;  Wu, Hong;  Zou, Fengming;  Yan, Xiao-E 收藏  |  浏览/下载：16/0  |  提交时间：2018/07/26 Discovery of (R)-1-(3-(4-Amino-3-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (CHMFL-EGFR-202) as a Novel Irreversible EGFR Mutant Kinase Inhibitor with a Distinct Binding Mode 期刊论文 JOURNAL OF MEDICINAL CHEMISTRY, 2017, 卷号: 60, 期号: 7, 页码: 2944-2962 作者:  Wang, Aoli;  Li, Xixiang;  Wu, Hong;  Zou, Fengming;  Yan, Xiao-E 收藏  |  浏览/下载：7/0  |  提交时间：2018/07/26 Discovery and characterization of a novel irreversible EGFR mutants selective and potent kinase inhibitor CHMFL-EGFR-26 with a distinct binding mode 期刊论文 ONCOTARGET, 2017, 卷号: 8, 期号: 11, 页码: 18359-18372 作者:  Hu, Chen;  Wang, Aoli;  Wu, Hong;  Qi, Ziping;  Li, Xixiang 收藏  |  浏览/下载：44/0  |  提交时间：2018/07/04 Egfr  Egfrt790m  Nsclc  Kinase Inhibitors  Drug Resistance